AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22706692 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 89784
Study 22706692 — intervention group
Group type: COMPARATOR
Intervention: Conventional Papanicolaou (CP) smear
Number of subjects: 89784
Study 20403018 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (mean = 0.12 g% breath alcohol concentration)
Number of subjects: 196
Study 20403018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 18316629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose increased to 12 mM)
Number of subjects: 24
Study 18316629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia (plasma insulin increased to 400 pmol/L)
Number of subjects: 24
Study 16273794 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR Core Data Set
Number of subjects: 0
Study 16273794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled index of patient self-report questionnaire measures
Number of subjects: 0
Study 16273794 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS
Number of subjects: 0
Study 16273794 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 12610003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12610003 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg daily (Irb150)
Number of subjects: 43
Study 12610003 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily (Irb300)
Number of subjects: 43
Study 10480767 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 89
Study 10480767 — intervention group
Group type: COMPARATOR
Intervention: human insulin 30/70
Number of subjects: 89
Study 8602660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg‐1 cisatracurium
Number of subjects: 20
Study 8602660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg‐1 cisatracurium
Number of subjects: 20
Study 1768553 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support jet ventilation (IPSTGIT)
Number of subjects: 10
Study 6461281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 mcg from a metered dose inhaler)
Number of subjects: 12
Study 6461281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31851256 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention via telephone for 3 months
Number of subjects: 101
Study 31851256 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (Control Group)
Number of subjects: 101
Study 28781108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg once weekly for 48 weeks
Number of subjects: 62
Study 28781108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26687300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 202
Study 26687300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine without folic acid
Number of subjects: 202
Study 26687300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine with folic acid
Number of subjects: 202
Study 26687300 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 202
Study 24953276 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL (Radioguided Occult Lesion Localization)
Number of subjects: 20
Study 24953276 — intervention group
Group type: COMPARATOR
Intervention: IOUS (Intraoperative Ultrasonography)
Number of subjects: 20
Study 22908773 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate and dry extract of Agropyrum repens (CalcoMEV) at the dose of 24 mEq of potassium citrate and 100 mg of dry extract of Agropyrum repens bis in die
Number of subjects: 50
Study 22908773 — intervention group
Group type: COMPARATOR
Intervention: Potassium citrate at a dose of 20 mEq ter in die
Number of subjects: 50
Study 21189142 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Number of subjects: 34
Study 21189142 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 34
Study 17661767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sotalol (80 mg twice daily) and magnesium supplementation
Number of subjects: 49
Study 17661767 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched, n = 844)
Number of subjects: 49
Study 17661767 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant patients
Number of subjects: 49
Study 16049806 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 676
Study 16049806 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype and formerly smoked
Number of subjects: 676
Study 16049806 — intervention group
Group type: COMPARATOR
Intervention: Current smokers who smoked 20 cigarettes or more per day
Number of subjects: 676
Study 16049806 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of three or more putative at risk genotypes
Number of subjects: 676
Study 11940138 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm 0.2% chlorhexidine rinse at 47 degrees C
Number of subjects: 10
Study 11940138 — intervention group
Group type: COMPARATOR
Intervention: Cold 0.2% chlorhexidine rinse at 18 degrees C
Number of subjects: 10
Study 10394161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory classification (good, intermediate, poor)
Number of subjects: 111
Study 10394161 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor microcirculatory group
Number of subjects: 111
Study 10394161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate microcirculatory group
Number of subjects: 111
Study 10394161 — intervention group
Group type: EXPERIMENTAL
Intervention: Good microcirculatory group
Number of subjects: 111
Study 1390141 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% solution of a commercial dish-washing product (three times/day, for 15 min, at 37 degrees C) for 3 weeks
Number of subjects: 18
Study 1390141 — intervention group
Group type: COMPARATOR
Intervention: Warm tap-water (control experiment)
Number of subjects: 18
Study 3162108 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 21
Study 3162108 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study 31647496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks
Number of subjects: 213
Study 31647496 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) at baseline
Number of subjects: 213
Study 29800014 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar-powered oxygen delivery
Number of subjects: 0
Study 29800014 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen delivery using compressed oxygen cylinders
Number of subjects: 0
Study 27362442 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE (2.3 g/day)
Number of subjects: 24
Study 27362442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26176940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA (4.5 mg/kg/day for low risk DGF, 2.5 mg/kg/day for high risk DGF)
Number of subjects: 162
Study 26176940 — intervention group
Group type: COMPARATOR
Intervention: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA
Number of subjects: 162
Study 23714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg three times per week for 3 months
Number of subjects: 30
Study 23714268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21621886 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume enteral supplement containing key nutrients
Number of subjects: 58
Study 21621886 — intervention group
Group type: COMPARATOR
Intervention: Diluted standard nutrition solution
Number of subjects: 58
Study 18291290 — intervention group
Group type: EXPERIMENTAL
Intervention: History of substance use disorder (SUD)
Number of subjects: 127
Study 18291290 — intervention group
Group type: COMPARATOR
Intervention: No history of substance use disorder (SUD)
Number of subjects: 127
Study 16824845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1351
Study 16824845 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus GPIIb/IIIa inhibitors
Number of subjects: 1351
Study 12959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low activity radioactive stenting (n = 18)
Number of subjects: 128
Study 12959730 — intervention group
Group type: EXPERIMENTAL
Intervention: High activity radioactive stenting (n = 26)
Number of subjects: 128
Study 12959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-end radioactive stenting (n = 18)
Number of subjects: 128
Study 12959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based radiation (Novoste Betacath (n = 39) and Guidant (n = 27))
Number of subjects: 128
Study 12959730 — intervention group
Group type: COMPARATOR
Intervention: Control group (Percutaneous transluminal coronary angioplasty with (n = 48) and without (n = 22) stent implantation)
Number of subjects: 128
Study 12959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 128
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB (Sentinel Lymph Node Biopsy)
Number of subjects: 0
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐α(2b)
Number of subjects: 0
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α(2b)
Number of subjects: 0
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR detection of tyrosinase in SLNs
Number of subjects: 0
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy or adjuvant IFN‐α(2b) therapy
Number of subjects: 0
Study 10836008 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR analysis of peripheral blood and bone marrow
Number of subjects: 0
Study 9643529 — intervention group
Group type: EXPERIMENTAL
Intervention: GMDP solution (0.5-1.0 mg daily)
Number of subjects: 63
Study 9643529 — intervention group
Group type: EXPERIMENTAL
Intervention: GMDP solution (1.5 mg/kg daily)
Number of subjects: 63
Study 9643529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9643529 — intervention group
Group type: EXPERIMENTAL
Intervention: GMDP solution
Number of subjects: 63
Study 7621303 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (40mg/day)
Number of subjects: 44
Study 7621303 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid (1500mg/day)
Number of subjects: 44
Study 7621303 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 20mg/day and Nicotinic acid 1000mg/day)
Number of subjects: 44
Study 3258558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 2.5 micrograms
Number of subjects: 10
Study 3258558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 10 micrograms
Number of subjects: 10
Study 3258558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 25 micrograms
Number of subjects: 10
Study 3258558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31584311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apple (120 kcal serving, twice daily)
Number of subjects: 38
Study 31584311 — intervention group
Group type: COMPARATOR
Intervention: Control snack (muffin, 120 kcal serving, twice daily)
Number of subjects: 38
Study 30043713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 285
Study 30043713 — intervention group
Group type: COMPARATOR
Intervention: Prostatectomy
Number of subjects: 285
Study 24726378 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture-based cartilage repair treatment
Number of subjects: 78
Study 24726378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing conditions
Number of subjects: 78
Study 24198887 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy (scaling & root planing) in Group B
Number of subjects: 40
Study 24198887 — intervention group
Group type: COMPARATOR
Intervention: No periodontal treatment in Group A
Number of subjects: 40
Study 18665846 — intervention group
Group type: EXPERIMENTAL
Intervention: Research during acute epidemics
Number of subjects: 0
Study 18665846 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement, public notification, and good information management
Number of subjects: 0
Study 18665846 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts to maintain individual consent
Number of subjects: 0
Study 18665846 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of data safety management boards
Number of subjects: 0
Study 18665846 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing the social value of research
Number of subjects: 0
Study 27950663 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF 50 mug/ml
Number of subjects: 113
Study 27950663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 16634381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led pre-operative assessment
Number of subjects: 595
Study 16634381 — intervention group
Group type: COMPARATOR
Intervention: Junior doctor-led pre-operative assessment (Control)
Number of subjects: 595
Study 12928686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 28
Study 10789889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered prior to both encoding and retrieval
Number of subjects: 48
Study 10789889 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered prior to both encoding and retrieval
Number of subjects: 48
Study 10789889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administered prior to encoding and retrieval
Number of subjects: 48
Study 8918499 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conservation treatment (lumpectomy) in node-negative trials
Number of subjects: 5172
Study 8918499 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conservation treatment (lumpectomy) in node-positive trials
Number of subjects: 5172
Study 8918499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy use with tumor size <= 1 cm and negative nodes
Number of subjects: 5172
Study 8918499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy rates across systemic risk strata
Number of subjects: 5172
Study 8918499 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of lower lumpectomy use
Number of subjects: 5172
Study 1442657 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (added to diet four times per day for 6 weeks)
Number of subjects: 0
Study 1442657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (added to diet four times per day for 6 weeks)
Number of subjects: 0
Study 3880685 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0
Study 3880685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 0
Study 3880685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30663187 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CGM (80% of the time)
Number of subjects: 151
Study 30663187 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous CGM (40% of the time)
Number of subjects: 151
Study 30663187 — intervention group
Group type: COMPARATOR
Intervention: Return to self-monitoring of blood glucose
Number of subjects: 151
Study 30663187 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after 3 months of RT-CGM)
Number of subjects: 151
Study 30663187 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time RT-CGM for 3 months
Number of subjects: 151
Study 29715529 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Health
Number of subjects: 364
Study 29715529 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364
Study 29715529 — intervention group
Group type: COMPARATOR
Intervention: Video control
Number of subjects: 364
Study 26924051 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255
Study 26924051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 24271056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 1502
Study 24271056 — intervention group
Group type: COMPARATOR
Intervention: Exemestane alone
Number of subjects: 1502
Study 24271056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (tamoxifen followed by exemestane)
Number of subjects: 1502
Study 22106843 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004
Number of subjects: 418
Study 22106843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 21055087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole prophylaxis
Number of subjects: 224
Study 21055087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluconazole prophylaxis)
Number of subjects: 224
Study 17546459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with prior expiratory muscle fatigue (EMF)
Number of subjects: 12
Study 17546459 — intervention group
Group type: COMPARATOR
Intervention: Control exercise (without prior EMF)
Number of subjects: 12
Study 17546459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with prior EMF
Number of subjects: 12
Study 16266450 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt fibrinolytic therapy
Number of subjects: 1120
Study 16266450 — intervention group
Group type: COMPARATOR
Intervention: UK group
Number of subjects: 1120
Study 16266450 — intervention group
Group type: COMPARATOR
Intervention: SK group
Number of subjects: 1120
Study 16266450 — intervention group
Group type: COMPARATOR
Intervention: rt-PA group
Number of subjects: 1120
Study 16266450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aborted AMI patients
Number of subjects: 1120
Study 12049013 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70
Study 12049013 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (control group)
Number of subjects: 70
Study 10381663 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 55
Study 10381663 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 55
Study 7573843 — intervention group
Group type: EXPERIMENTAL
Intervention: FPANS 100 micrograms od
Number of subjects: 143
Study 7573843 — intervention group
Group type: EXPERIMENTAL
Intervention: FPANS 200 micrograms od
Number of subjects: 143
Study 7573843 — intervention group
Group type: COMPARATOR
Intervention: Placebo od
Number of subjects: 143
Study 2324541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (ProHibit)
Number of subjects: 50
Study 371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 160 mg in a slow-release formulation with cyclopenthiazide 0.25 mg and potassium chloride 600 mg given once daily
Number of subjects: 238
Study 371021 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 250 mg 3 times daily
Number of subjects: 238
Study 31392790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 29
Study 31392790 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee exercises
Number of subjects: 29
Study 27751610 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 exchanges
Number of subjects: 139
Study 27751610 — intervention group
Group type: COMPARATOR
Intervention: 4 exchanges
Number of subjects: 139
Study 25318667 — intervention group
Group type: EXPERIMENTAL
Intervention: flow‐SNIPPV
Number of subjects: 19
Study 25318667 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 19
Study 25318667 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 19
Study 23425607 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV(new WS) vaccine
Number of subjects: 0
Study 23425607 — intervention group
Group type: COMPARATOR
Intervention: MMRV vaccine
Number of subjects: 0
Study 22211198 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy in addition to physical therapy
Number of subjects: 26
Study 22211198 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 19826291 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (TR) for 20 minutes at approximately 70-80% of heart rate reserve
Number of subjects: 15
Study 19826291 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) for 20 minutes (20 repetitions at 40% of 1 repetition maximum)
Number of subjects: 15
Study 19826291 — intervention group
Group type: COMPARATOR
Intervention: Control session without exercise (CON)
Number of subjects: 15
Study 16506871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (IMT) at 80% of maximal effort for 8 weeks
Number of subjects: 20
Study 16506871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 12801243 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) 0.5 g in 250 ml of 0.1% lithium carbonate/4% dextrose vehicle
Number of subjects: 20
Study 12801243 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 20
Study 11063279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE‐inhibitors, protocol‐driven tight control of blood glucose, blood pressure and cholesterol)
Number of subjects: 3000
Study 11063279 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (according to current national guidelines)
Number of subjects: 3000
Study 9115065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) for 45 days
Number of subjects: 89
Study 9115065 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 45 days
Number of subjects: 89
Study 1492231 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 1492231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy regimens supported by GM-CSF
Number of subjects: 0